• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Regulation of the Expression of SARS-CoV-2 Receptor Angiotensin-Converting Enzyme 2 in Nasal Mucosa
CONCLUSION: Inflammatory endotype affects ACE2 expression in the nasal mucosa and influences susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In particular, type 2 inflammation could downregulate ACE2 expression in the nasal mucosa and reduces susceptibility to SARS-CoV-2 in patients with CRSwNP. Although in vivo experiments are required, administration of SCFAs to the nasal cavity might be worthy of consideration as a preventative or therapeutic strategy for the early-stage COVID-19.PMID:34232770 | DOI:10.1177/19458924211027798
Source: American Journal of Rhinology and Allergy - July 7, 2021 Category: ENT & OMF Authors: Tetsuji Takabayashi Kanako Yoshida Yoshimasa Imoto Robert P Schleimer Shigeharu Fujieda Source Type: research

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic...
Source: Roche Media News - April 13, 2021 Category: Pharmaceuticals Source Type: news

Inflammatory endotypes of CRSwNP and responses to COVID-19
Purpose of review Coronavirus disease 2019 (COVID-19), a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has quickly become a great public health hazard globally. Nasal epithelial cells are an important site for SARS-CoV-2 infection and replication. The purpose of this review is to summarize recent findings on the endotypes of chronic rhinosinusitis with nasal polyps (CRSwNP) and the potential impact of SARS-CoV-2 infection. Recent findings Endotypes of CRSwNP are characterized by type 1, type 2 and type 3 inflammation according to patterns of inflammatory cells and the cytokines ...
Source: Current Opinion in Allergy and Clinical Immunology - December 26, 2020 Category: Allergy & Immunology Tags: RHINITIS, SINUSITIS AND UPPER AIRWAY DISEASE: Edited by Ruby Pawankar and David P. Skoner Source Type: research

Fauci out of surgery for vocal cord polyp
White House Coronavirus Task Force member Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, confirmed to CNN that he had surgery Thursday morning to remove a polyp on his vocal cord.
Source: CNN.com - Health - August 21, 2020 Category: Consumer Health News Source Type: news

The clinical relevance of the clinical cytological grading in patients with chronic rhinosinusitis with nasal polyps
Smell dysfunction is a common symptom and has a diagnostic value in the workup of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) as recently outlined by Mullol et  al.1 Notably, loss of smell has been proposed as one of the main criteria for an indication of and response to the new biological treatments.2 Of note, it has been very recently reported that a significant part (20%-60%) of the patients with coronavirus disease 2019 (COVID-19) experienced the loss of smell; anosmia can be the first presenting symptom and so the European Rhinologic Society advised that patients with sudden-onset loss of smell sh...
Source: Journal of Allergy and Clinical Immunology - June 23, 2020 Category: Allergy & Immunology Authors: Matteo Gelardi, Michele Cassano, Giorgio Ciprandi Tags: Correspondence Source Type: research

COVID-19 infection in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab
A patient with severe CRSwNP, asthma, and NSAIDS received dupilumab treatment. Three weeks after therapy onset, the patient was diagnosed with Covid-19, had a mild course of the disease, and fully recovered from the infection.
Source: Journal of Allergy and Clinical Immunology - May 13, 2020 Category: Allergy & Immunology Authors: Ulrike F örster-Ruhrmann, Agnieszka J. Szczepek, habil Claus Bachert, habil Heidi Olze Source Type: research

COVID-19 in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab
mAbs (biologics) such as dupilumab, a fully human mAb blocking IL-4 and IL-13 signaling, started recently to be successfully used also for the treatment of severe forms of chronic rhinosinusitis with nasal polyps (CRSwNP).1 Currently, no data are available on whether the therapy with dupilumab influences the risk of infection with the coronavirus (severe acute respiratory disease coronavirus 2 [SARS-CoV-2]) or whether it modulates the course of coronavirus disease 2019 (COVID-19).
Source: Journal of Allergy and Clinical Immunology - May 13, 2020 Category: Allergy & Immunology Authors: Ulrike F örster-Ruhrmann, Agnieszka J. Szczepek, Claus Bachert, Heidi Olze Tags: Letter to the Editor Source Type: research

Positionspapier: Empfehlungen zur Behandlung der chronischen Rhinosinusitis w ährend der COVID-19-Pandemie im deutschen Gesundheitssystem – Empfehlungen des Ärzteverbandes Deutscher Allergologen (AeDA) und der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Halschirurgie (DGHNOKHC) – Diese Empfehlungen basieren auf dem EAACI Positionspapier „Treatment of chronic RhinoSinusitis with nasal polyps (CRSwNP) in the COVID-19 pandemics – An EAACI Position Paper”, Allergy, 2020 und wurden auf die Situation im deutschen Gesundheitswesen angepasst
Laryngo-Rhino-Otol DOI: 10.1055/a-1164-9696 Hintergrund Von der chronischen Rhinosinusitis (CRS) sind weltweit etwa 5–12 % der Allgemeinbevölkerung betroffen. Die CRS gilt als chronische Atemwegserkrankung, die nach den Empfehlungen der WHO ein Risikofaktor für COVID-19-Patienten sein kann. Die entzündlichen Veränderungen der Nasenschleimhäute bei chronischer Rhinosinusitis mit Nasenpolypen (CRSwNP) sind in den meisten Fällen vom Entzündungsendotyp 2 (T2). Methoden Der aktuelle Wissensstand sowohl zu COVID-19 als auch zu den Behandlungsmöglichkeiten von CRSwNP wurde durch eine Literaturrecherche in Me...
Source: Laryngo- Rhino- Otologie - May 7, 2020 Category: ENT & OMF Authors: Klimek, L. Becker, S. Buhl, R. Chaker, A. M. Huppertz, T. Hoffmann, T. K. Dazert, S. Deitmer, T. F örster-Ruhrmann, U. Olze, H. Hagemann, J. Plontke, S. K. Wrede, H. Schlenter, W. Welkoborsky, H. J. Wollenberg, B. Beule, A. G. Rudack, C. Strieth, S. M ö Tags: Leitlinien und Empfehlungen Source Type: research